DateTitle
13-8-2019 1:29 EDT Six-month interim report (Q2) 2019
12-8-2019 11:06 EDT ALK upgrades its full-year financial outlook due to strong growth
9-8-2019 4:00 EDT ALK announces new epinephrine auto-injector strategy based on innovative new product for the USA
6-8-2019 4:00 EDT Release date of six-month interim report (Q2) 2019 for ALK and audio cast
24-6-2019 3:00 EDT ALK submits registration application for tree SLIT-tablet in Canada
7-6-2019 8:57 EDT ALK obtains European approval for its tree SLIT-tablet against allergic rhinitis
13-5-2019 11:29 EDT Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
9-5-2019 1:30 EDT Three-month interim report (Q1) 2019
2-5-2019 3:40 EDT Release date of three-month interim report 2019 for ALK and audio cast
21-3-2019 12:05 EDT Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
21-3-2019 11:57 EDT Grant of share options and performance shares to members of the Board of Management and key employees
13-3-2019 12:13 EDT Annual General Meeting in ALK-Abelló A/S held on 13 March 2019
12-3-2019 4:58 EDT The pollen season kicks off with an award-winning pollen app
4-3-2019 10:53 EST Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
26-2-2019 3:03 EST New data shows ALK’s house dust mite SLIT-tablet significantly improves quality of sleep for allergic rhinitis patients
14-2-2019 8:00 EST Annual General Meeting in ALK-Abelló A/S on 13 March 2019
7-2-2019 1:32 EST ALK releases its annual report 2018
30-1-2019 3:48 EST Release date of annual report 2018 for ALK and audio cast
15-1-2019 8:22 EST Large-scale paediatric SLIT-tablet trial meets primary endpoint, confirming potential in children
15-1-2019 3:58 EST ALK's Board of Directors to nominate Vincent Warnery as new member of the Board
11-1-2019 10:44 EST ALK appoints new Head of Product Supply